Clinical Trial Update: Single Ascending-dose Study of the Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Subjects [Phase 1]

View source ↗

Summary

Phase 1 single ascending-dose study assessing safety, tolerability, and pharmacokinetics of REGN1908-1909 in allergic adult subjects has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Diseases

Drugs mentioned

• REGN1908-1909

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Allergy | Phase 1 | Status: COMPLETED